Study selection and analysis: Eligible studies were randomised clinical trials comparing antidepressants plus psychotherapy (problem solving, interpersonal, cognitive, behavioural, marital, and psychodynamic therapies) with antidepressant treatment alone. Exclusions: non-pharmacological intervention other than psychotherapy; subsequent publications from an already published trial (data subsets or long term follow up). Data were extracted on diagnosis, sex, age, type of antidepressant, type of intervention, and study duration. Study quality and duration were used to perform meta-regression analysis on random effect estimates.
Outcomes: Response rate; dropout rate.
MAIN RESULTS
Sixteen studies met inclusion criteria. 910 people received psychotherapy plus antidepressants and 932 people received antidepressants alone (median female: 65%; study length: 4-24 weeks; dose equivalent of imipramine hydrochloride: 100-269 mg/day). Psychotherapy plus antidepressants significantly improved response rates compared with antidepressants alone in people with depression (see http://www.ebmentalhealth.com/supplemental for table). There were no significant differences in dropout rate between groups. Study length had no effect on response rate; however studies more than 12 weeks long had significantly reduced dropout rates.
CONCLUSIONS
Psychotherapy in combination with antidepressants significantly improves response rates in people with depression. For studies longer than 12 weeks, the combined therapy also significantly reduces dropout rates.
NOTES
Standardisation of antidepressant doses was carried out by conversion to the equivalent dose of imipramine hydrochloride. Rate difference analysis showed no change in non-response rate (0.4%) and a significant reduction in dropout rate (212.9%) (see 3 4 According to Pampallona et al, the few controlled studies that have examined adherence involve interventions that are multilayered, thus obfuscating factors that affect adherence. Further, the authors report that these few controlled studies on ADM adherence do not systematically measure clinical outcomes such as remission. Thus, it is unclear which factors influence adherence and how it is related to clinical outcome.
The authors examined the effects on outcomes and adherence of combined treatment (pharmacotherapy plus psychotherapy) versus pharmacotherapy only by performing a meta-analysis on 16 randomised clinical trials. Each clinical trial included pharmacotherapy and pharmacotherapy plus psychotherapy conditions, as well as data on outcome measures.
The authors found that combined treatment reduced non-response to treatment, thus participants experienced some, if not total alleviation of depressive symptoms. Further, the addition of psychotherapy to pharmacotherapy increased participant retention in studies of 12 weeks or longer; however, there was no significant decrease in non-response rate above and beyond that observed during the first 12 weeks or in studies less than 12 weeks in length.
The authors point out that the precise causes of the improved outcomes achieved with combined treatment are unknown and future studies are needed. We agree with the authors that future research on this topic holds considerable promise. Our research on ADM treatment of depression is guided by the notion that the patient-pharmacotherapist relationship, a variable often studied in psychotherapy trials and considered crucial in achieving therapeutic outcomes, 5 is largely overlooked in studies of adherence to ADM. It is our hope that research on psychological factors involved in ADM treatment adherence will help to further integrate the findings from the somewhat disparate depression treatment literature on psychosocial and biological approaches with the promise of providing further benefit to patients.
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